[Skip to Content]
[Skip to Content Landing]
Comment & Response
August 4, 2020

Errors in Trial of Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19

Author Affiliations
  • 1Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, China
JAMA. 2020;324(5):518-519. doi:10.1001/jama.2020.12607

To the Editor My coauthors and I recently undertook a review of the Original Investigation “Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial,” published online in JAMA on June 3, 2020.1 In this trial, we assessed the effect of convalescent plasma therapy in addition to standard treatment vs standard treatment alone among 103 patients with coronavirus disease 2019 (COVID-19), stratified by disease severity. The primary outcome was time to clinical improvement within 28 days. We found that among patients with severe or life-threatening COVID-19, convalescent plasma therapy added to standard treatment, compared with standard treatment alone, did not result in a statistically significant improvement in time to clinical improvement within 28 days.

×